
Partner
DART-Met is a programmable sensing platform designed to reveal biochemical signatures of liver disease and injury that conventional blood tests may miss. Suraj Pavagada, PhD, a Stanford radiology postdoc, is developing it. He came in with two ideas for where to start: catching liver injury earlier in drug trials, or picking patients for MASH trials without a biopsy.
Challenge
He knew the science. What he didn’t know yet was who would buy it first and why, and how to make that case to investors. He asked Sleuth’s analysts to do the market work.
Approach
Outcome
“My father’s liver panels read normal, normal, normal, and then—suddenly, late‑stage cirrhosis. The damage starts long before it shows up on those tests. That gap is the reason DART‑Met exists.”

Suraj Pavagada, PhD
Stanford researcher
The DART-Met platform detects liver injury, so the question was where it would change a decision, and who would pay. Sleuth’s analysts pulled ten years of liver-safety setbacks, with the FDA actions and trial costs around them. Two lessons cast doubt on the original plan.
More than half surfaced at Phase 3 or later, the costliest stretch of development. Catching failures early, the market he’d planned to lead with, is the bigger prize, but proving a test can do it would take years of trial data.

He’d guessed cancer drugs would be where the most liver safety setbacks were. Only 2 of the 25 setbacks Sleuth analyzed were in oncology. Twenty were small molecules outside cancer. Those developers, not oncology teams, became his targeted buyers later.

Suraj planned to pitch early detection across drug trials. The analysis showed that would be slow to prove, so Sleuth looked at MASH trial screening, which he's now weighing alongside it.

“Founders need outside input to pressure test their own assumptions. Sleuth’s analysts showed us where liver safety really breaks down in drug development, and it sharpened our commercialization thinking before investor discussions.”
Suraj Pavagada, PhD